Given the critical functions of histone methylome in AML, the first HMT inhibitor targeting DOT1L, EPZ477759 and its second-generation derivative, EPZ567660 have been developed and tested for suppressing MLL leukaemia. The gene discussed is KMT2A; the disease is leukemia.